** Shares of drug developer Q32 Bio fall 67.64% to $7.90 after market
** QTTB says its experimental drug bempikibart failed to meet the main goal in a part of a mid-stage trial studying it in patients with atopic dermatitis
** The two-part trial was evaluating the drug in adults with atopic dermatitis, a condition that causes dry, itchy and inflamed skin
** Co plans to conduct a review to better understand the results
** In another trial, bempikibart showed improvement in patients with alopecia areata, an autoimmune disease that causes hair loss in patches
** Based on the results, QTTB plans to advance development of bempikibart in patients with the hair condition
** Up to last close, stock up ~123% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.